A Study Offering Treatment with 3F8 and GM-CSF in Patients with High-Risk Neuroblastoma

Protocol
13-260
Full Title
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Disease Status
Relapsed/Refractory
Purpose

3F8 is an antibody that attaches to neuroblastoma cells and helps focus a patient’s own immune system — especially white blood cells — to attack neuroblastoma. Granulocytes make up one kind of white blood cells. GM-CSF increases the number of granulocytes, and makes them better killers of cancer.

3F8 is an investigational drug that has been used in patients with neuroblastoma at Memorial Sloan Kettering for many years. This study will allow 3F8 to be given, in combination with GM-CSF, to patients with high-risk neuroblastoma. This includes patients who have no signs of cancer after other treatments but whose cancer has a chance of coming back (relapsing) and patients whose cancer is not responding to other kinds of treatment.

Eligibility

Patients who are eligible to participate include children and adults with high-risk neuroblastoma whose disease is (1) in remission but has a chance of relapsing, or (2) not responding to other treatments.

For more information about this study and to inquire about eligibility, please contact Dr. Brian Kushner at 212-639-6793.

Disease(s)
Neuroblastoma
Locations
Related Diseases

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »